1. Home
  2. UXIN vs REPL Comparison

UXIN vs REPL Comparison

Compare UXIN & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Uxin Limited ADS

UXIN

Uxin Limited ADS

N/A

Current Price

$3.53

Market Cap

756.6M

ML Signal

N/A

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

N/A

Current Price

$6.82

Market Cap

692.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UXIN
REPL
Founded
2011
2015
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
756.6M
692.8M
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
UXIN
REPL
Price
$3.53
$6.82
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$11.13
AVG Volume (30 Days)
115.6K
1.2M
Earning Date
03-13-2026
02-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.25
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$237.18
N/A
Revenue Next Year
$145.46
N/A
P/E Ratio
$4.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.45
$2.68
52 Week High
$5.40
$13.24

Technical Indicators

Market Signals
Indicator
UXIN
REPL
Relative Strength Index (RSI) 50.10 41.92
Support Level $3.21 $6.89
Resistance Level $3.83 $10.54
Average True Range (ATR) 0.19 0.53
MACD -0.01 -0.07
Stochastic Oscillator 45.16 18.10

Price Performance

Historical Comparison
UXIN
REPL

About UXIN Uxin Limited ADS

Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates used car e-commerce platforms through its mobile applications and websites. It facilitates used car transaction services and financing solutions offered by third-party financing partners to buyers for their used car purchases. The company generates revenue through sales of the commission of salvage car sales, and interest income from the financial lease. The Group generates its revenues in China, and assets of the company are also located in China Area.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: